Cel Sci Corporation (CVM)

[Biobonic]

Cel Sci is gaining on the finish line, but it does seem to be a moving target.

Q filing June 2020

Since the Company launched its Phase 3 clinical trial for Multikine, the Company has incurred expenses of approximately $57.7 million as of June
30, 2020 on direct costs for the Phase 3 clinical trial. The Company estimates it will incur additional expenses of approximately $5.3 million for the remainder of the Phase 3 clinical trial.

Annual filing Sept 2020

Since CEL-SCI launched its Phase 3 clinical trial for Multikine, CEL-SCI has incurred expenses of approximately $58.9 million as of September 30, 2020 on direct costs for the Phase 3 clinical trial. CEL-SCI estimates it will incur additional expenses of approximately $5.9 million for the remainder of the Phase 3 clinical trial and the filing of the clinical study report to the FDA

Q filing Dec 2020

Since the Company launched its Phase 3 clinical trial for Multikine, the Company has incurred expenses of approximately $60.2 million as of December 31, 2020 on direct costs for the Phase 3 clinical trial and the filing of the clinical study report to the FDA. The Company estimates it will incur additional expenses of approximately $5.1 million for the remainder of the Phase 3 clinical trial.

Q filing for Mar 2021

Since the Company launched its Phase 3 clinical trial for Multikine, the Company has incurred expenses of approximately $60.8 million as of
March 31, 2021 on direct costs for the Phase 3 clinical trial. The Company estimates it will incur additional expenses of approximately $4.4 million for the remainder of the Phase 3 clinical trial and the filing of the clinical study report to the FDA.


FDA fee table

User Fee Type 2021
Application Fee – Clinical Data Reqd $ $2,875,842
Program Fee $336,432